首页|Enhancing metformin-induced tumor metabolism destruction by glucose oxidase for triple-combination therapy

Enhancing metformin-induced tumor metabolism destruction by glucose oxidase for triple-combination therapy

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Despite decades of laboratory and clinical trials,breast cancer remains the main cause of cancer-related disease burden in women.Considering the metabolism destruction effect of metformin(Met)and cancer cell starvation induced by glucose oxidase(GOx),after their efficient delivery to tumor sites,GOx and Met may consume a large amount of glucose and produce sufficient hydrogen peroxide in situ.Herein,a pH-responsive epigallocatechin gallate(EGCG)-conjugated low-molecular-weight chitosan(LC-EGCG,LE)nanoparticle(Met-GOx/Fe@LE NPs)was constructed.The coordination between iron ions(Fe3+)and EGCG in this nanoplatform can enhance the efficacy of chemodynamic therapy via the Fenton reaction.Met-GOx/Fe@LE NPs allow GOx to retain its enzymatic activity while simultaneously improving its stability.Moreover,this pH-responsive nanoplatform presents controllable drug release behavior.An in vivo biodistribution study showed that the intracranial accumulation of GOx delivered by this nano-platform was 3.6-fold higher than that of the free drug.The in vivo anticancer results indicated that this metabolism destruction/starvation/chemodynamic triple-combination therapy could induce increased apoptosis/death of tumor cells and reduce their proliferation.This triple-combination therapy approach is promising for efficient and targeted cancer treatment.

MetforminGlucose oxidaseMetabolism disruptionTumor starvationCombination cancer therapy

Rangrang Fan、Linrui Cai、Hao Liu、Hongxu Chen、Caili Chen、Gang Guo、Jianguo Xu

展开 >

Department of Neurosurgery and Institute of Neurosurgery,Cancer Center and State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Chengdu,610041,China

NMPA Key Laboratory for Technical Research on Drug Products in Vitro and in Vivo Correlation,Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE,National Drug Clinical-Trial Institution,West China Second Hospital,Sichuan University,Chengdu,610041,China

Department of Immunology,School of Basic Medical Sciences,Xinxiang Medical University,Xinxiang,Henan,453000,China

2024

10.1016/j.jpha.2023.09.015

药物分析学报(英文)
西安交通大学

药物分析学报(英文)

影响因子：0.244
ISSN：2095-1779
年,卷(期)：2024.14(3)